Related Experiment Video
Updated: Aug 16, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype
Nicolas Boissel1, Aline Renneville, Valeria Biggio
1Service d'Hématologie Adulte, Hôpital Saint-Louis, Paris, France. cpreudhomme@chru-lille.fr
Abstract:
Mutation of the nucleophosmin (NPM) gene has been reported as the most frequent mutation in acute myeloid leukemia (AML), especially in the presence of a normal karyotype. In this subgroup of intermediate-risk AML, the identification of other gene mutations (eg, FLT3, CCAAT/enhancer-binding protein-alpha [CEBPA]) has helped to refine the prognosis. This study explored the prevalence and the prognostic impact of NPM mutations in a cohort of 106 patients with normal-karyotype AML. NPM exon 12 mutations were detected by polymerase chain reaction (PCR) and fragment analysis for the insertion/deletion globally resulting in a 4-bp insertion. NPM mutations were detected in 47% of patients and were associated with a high white blood cell count, involvement of the monocytic lineage (M4/M5), and a decreased prevalence of CEBPA mutations. Complete remission rate and long-term outcome did not differ between NPM-mutated and -nonmutated patients. Prospective studies are needed to confirm the definitive place of NPM mutation detection to predict AML response to therapy.
Insights
Nucleophosmin (NPM) gene mutations are common in acute myeloid leukemia (AML) with normal karyotype. While NPM mutations are linked to specific AML subtypes, they did not impact complete remission rates or long-term outcomes in this study.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Nucleophosmin (NPM) gene mutations are the most frequent genetic alterations in acute myeloid leukemia (AML), particularly in patients with a normal karyotype.
- Identifying additional gene mutations, such as FLT3 and CCAAT/enhancer-binding protein-alpha (CEBPA), aids in refining prognosis for intermediate-risk AML.
- NPM mutations are prevalent in a specific AML subgroup, necessitating further investigation into their prognostic significance.
Purpose of the Study:
- To determine the prevalence of NPM gene mutations in a cohort of 106 patients diagnosed with normal-karyotype AML.
- To evaluate the prognostic impact of NPM mutations on patient outcomes, including complete remission rates and long-term survival.
- To explore the association between NPM mutations and other clinical and molecular characteristics in normal-karyotype AML.
Main Methods:
- NPM exon 12 mutations were identified using polymerase chain reaction (PCR) and fragment analysis, specifically detecting a 4-bp insertion/deletion.
- A cohort of 106 patients with normal-karyotype AML was analyzed for the presence of NPM mutations.
- Statistical analyses were performed to correlate NPM mutation status with clinical features and treatment outcomes.
Main Results:
- NPM mutations were detected in 47% of the patients with normal-karyotype AML.
- NPM mutations were significantly associated with higher white blood cell counts, monocytic lineage involvement (M4/M5), and a lower frequency of CEBPA mutations.
- No significant differences were observed in complete remission rates or long-term outcomes between patients with and without NPM mutations.
Conclusions:
- NPM mutations are a frequent finding in normal-karyotype AML and are associated with distinct clinical and molecular features.
- Despite their prevalence and associations, NPM mutations did not appear to influence the overall treatment response or long-term prognosis in this patient cohort.
- Further prospective studies are required to definitively establish the role of NPM mutation detection in predicting therapeutic response in AML.
